[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369939-105":59,"doc-detail-369939-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-of-a-recurrence-related-gene-signature-and-functional-role-of-mllt6-in-ovarian-cancer-progression-and-paclitaxel-resistance","Development of a recurrence-related gene signature and functional role of MLLT6 in ovarian cancer progression and Paclitaxel resistance","","Ovarian cancer is a lethal gynecologic malignancy characterized by high recurrence rates and poor prognosis. This study develops a recurrence-related gene signature (RRGS) to improve prognostic prediction and investigates MLLT6, a key RRGS gene, in ovarian cancer progression and Paclitaxel resistance. TCGA and GEO cohorts identified recurrence-associated differential genes and LASSO modeling built an eight-gene RRGS, validated in independent cohorts. Cellular assays assessed proliferation, migration, invasion, and drug resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-a-recurrence-related-gene-signature-and-functional-role-of-mllt6-in-ovarian-cancer-progression-and-paclitaxel-resistance/369939/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-a-recurrence-related-gene-signature-and-functional-role-of-mllt6-in-ovarian-cancer-progression-and-paclitaxel-resistance/369939.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of developing the RRGS in this study?","Question",{"text":112,"@type":113},"To create a recurrence-related gene signature that stratifies patients by prognosis and helps identify molecular mechanisms tied to recurrence in ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the recurrence-associated genes and RRGS constructed?",{"text":117,"@type":113},"Differentially expressed genes linked to recurrence were identified using TCGA and GEO, and LASSO regression was used to construct an eight-gene RRGS, followed by validation in independent cohorts.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does MLLT6 play in ovarian cancer and Paclitaxel resistance?",{"text":121,"@type":113},"MLLT6 is identified as the most significant prognostic marker among RRGS genes. MLLT6 knockdown suppresses ovarian cancer cell proliferation, migration, and invasion and increases Paclitaxel sensitivity by lowering IC50 values.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369939,1791587792,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Bao et al. Journal of Ovarian Research (2025) 18:224 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-025-01791-3](https://doi.org/10.1186/s13048-025-01791-3)  \nRESEARCH Open Access  \nDevelopment of a recurrence-related gene signature and functional role of MLLT6 in ovarian cancer progression and Paclitaxel resistance  \nQiufang Bao 1,2,3, Shaoyu Wang 1,2,3 and Linliang Hong4,5*  \nAbstract  \nObjective Ovarian cancer is one of the most lethal gynecological malignancies, with high recurrence rates and poor prognosis. Identifying molecular mechanisms underlying recurrence is critical for improving patient outcomes. This study aimed to develop a recurrence-related gene signature (RRGS) for prognosis and explore the role of Myeloid/ Lymphoid or Mixed-Lineage Leukemia; Translocated To 6 (MLLT6), a key gene within the RRGS, in ovarian cancer progression and drug resistance.  \nMethods TCGA and GEO cohorts were analyzed to identify differential ly expressed genes (DEGs) associated with recurrence. LASSO regression was applied to construct an eight-gene RRGS, which was validated in independent cohorts. Functional assays, including proliferation, migration, invasion, and drug resistance tests, were conducted in OVCAR3, TOV-21G and ES-2 cell lines to evaluate the role of MLLT6 .  \nResults The RRGS effectively stratified patients into high-and low-risk groups, with high RRGS scores correlating with poorer overall survival and progression-free survival. Among the RRGS genes, MLLT6 was identified as the most significant prognostic marker. Functional assays showed that MLLT6 knockdown inhibited ovarian cancer cell proliferation, migration, invasion, and significantly enhanced Paclitaxel sensitivity by reducing IC50 values. Conclusion The RRGS is a robust prognostic tool for ovarian cancer, and MLLT6 plays a critical role in tumor progression and drug resistance. Targeting MLLT6 may provide a novel therapeutic strategy to overcome Paclitaxel resistance and improve patient outcomes.  \nKeywords Ovarian cancer, Recurrence, Immunotherapy, Prognosis, MLLT6  \n*Correspondence: Linliang Hong [trap2008@163.com](trap2008@163.com)  \n1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Fujian Medical University, Fujian Medical University, Fuzhou 350005, China 2Department of Obstetrics and Gynecology, The First Clinical College of Fujian Medical University, Fuzhou 350108, China  \n3Department of Obstetrics and Gynecology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, 350212 Fuzhou, China  \n4Department of Pediatrics, The First Clinical College of Fujian Medical University, 350005, Fuzhou, China  \n5Department of Pediatrics, The First Affiliated Hospital, Fujian Medical University, 350108, Fuzhou, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nBao et al. Journal of Ovarian Research (2025) 18:224  \nIntroduction  \nOvarian cancer remains one of the most lethal gynecologi","cbCaiqqxgvt1eLJd","https://ap.wps.com/l/cbCaiqqxgvt1eLJd","pdf",12049296,18,"English","# Abstract\n# Introduction\n## Background and clinical challenge\n## Molecular drivers and research gap\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is the main goal of developing the RRGS in this study?\",\"answer\":\"To create a recurrence-related gene signature that stratifies patients by prognosis and helps identify molecular mechanisms tied to recurrence in ovarian cancer.\"},{\"question\":\"How were the recurrence-associated genes and RRGS constructed?\",\"answer\":\"Differentially expressed genes linked to recurrence were identified using TCGA and GEO, and LASSO regression was used to construct an eight-gene RRGS, followed by validation in independent cohorts.\"},{\"question\":\"What role does MLLT6 play in ovarian cancer and Paclitaxel resistance?\",\"answer\":\"MLLT6 is identified as the most significant prognostic marker among RRGS genes. MLLT6 knockdown suppresses ovarian cancer cell proliferation, migration, and invasion and increases Paclitaxel sensitivity by lowering IC50 values.\"}]","Development of a recurrence-related gene signature and functional role of MLLT6 in ovarian cancer progression and Paclitaxel resistance | PDF",1790185310,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e15465a6e045bebc7747d5e5dd34712.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c84b840925b4d0337a3f91b89c5451b0.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4528b0221d0ee361180e6d1591a3d17c.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a41688165276fbc1ffd468c6e29b887a.webp",980,1306]